Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692961 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL1498337 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL23912326 | 0.93 | BTK (0.55) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL15970543 | 0.88 | KMT2A (0.52) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL13920525 | 0.88 | KMT2A (0.52) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL16376312 | 0.87 | ALDH1A1 (0.43) | ALDH1A1MEN1TSHRKMT2AKDM4E | |
| SCHEMBL28627032 | 0.85 | BTK (0.55) | KMT2ABTKEPHX1KDM1AMAOB | |
| SCHEMBL2579193 | 0.85 | KMT2A (0.54) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL168732 | 0.85 | KMT2A (0.54) | ALDH1A1MEN1TSHRKMT2ABTK | |
| SCHEMBL168733 | 0.85 | KMT2A (0.54) | ALDH1A1MEN1TSHRKMT2ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024220626-A1 | SMALL MOLECULE MODULATORS OF OGG1 | AZKARRA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230257368-A1 | METHOD FOR PRODUCING 1,3-BENZODIOXOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-08-17 | — | — | US | disclosed |
| EP-4180426-A1 | METHOD FOR PRODUCING 1,3-BENZODIOXOLE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2023-05-17 | — | — | EP | disclosed |
| CN-116120213-A | Synthesis method of trans-4- (tert-butoxycarbonylamino) cyclohexane carboxylic acid | 重庆医药高等专科学校 | 2023-05-16 | — | — | CN | disclosed |
| CN-116082192-A | Preparation method of trans-4- (tert-butoxycarbonylamino) cyclohexane carboxylic acid | 重庆医药高等专科学校 | 2023-05-09 | — | — | CN | disclosed |
| CN-116018335-A | Process for preparing 1, 3-benzodioxole derivatives | 第一三共株式会社 | 2023-04-25 | — | — | CN | disclosed |
| US-20230113609-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113402428-B | Preparation method of trans-4- (tert-butoxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof | 重庆医药高等专科学校 | 2023-03-03 | — | — | CN | disclosed |
| EP-4069702-A1 | SSTR5 ANTAGONISTS | Kallyope, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-113402428-A | Preparation method of trans-4- (tert-butoxycarbonylamino) cyclohexanecarboxylic acid and intermediate thereof | 重庆医药高等专科学校 | 2021-09-17 | — | — | CN | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | SEKI MASAHIKO | 2009-01-22 | — | — | US | disclosed |
| US-7439368-B2 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-10-21 | — | — | US | disclosed |
| US-20060173188-A1 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1640373-A1 | PROCESS FOR PRODUCING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | TANABE SEIYAKU CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-0686625-B1 | ANTHRANILIC ACID DERIVATIVE | EISAI CO LTD (JP) | 1999-05-26 | — | — | EP | disclosed |
| US-5716993-A | PHOSPHODIESTERASE ENZYME INHIBITOR FOR TREATING CARDIOVASCULAR DISORDER, ANGINA PECTORIS, HYPERTENSION, ASTHMA | EISAI CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| CN-1118595-A | Anthranilic acid derivative | EISAI CO LTD (JP) | 1996-03-13 | — | — | CN | disclosed |
| EP-0686625-A1 | ANTHRANILIC ACID DERIVATIVE | Eisai Co., Ltd. (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113609-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | ALDH1A1 2825/4885MEN1 2406/4885TSHR 128/4885 |
| US-20230257368-A1 | METHOD FOR PRODUCING 1,3-BENZODIOXOLE DERIVATIVE | BBOX1, CBR3, CBR1 | ALDH1A1 437/4885MEN1 4699/4885TSHR 3352/4885 |
| US-20060173188-A1 | Process for producing 3-acylaminobenzofuran-2-carboxylic acid derivative | F12, F3, F11 | ALDH1A1 661/4885MEN1 1551/4885TSHR 1645/4885 |
| US-20090023918-A1 | PROCESS FOR PREPARING 3-ACYLAMINOBENZOFURAN-2-CARBOXYLIC ACID DERIVATIVE | F12, F3, F11 | ALDH1A1 690/4885MEN1 1318/4885TSHR 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.